Galectin Therapeutics Inc. (GALT:NASDAQ) closed at $3.50 on October 19, 2026, down 3.45% on the day. The stock trades 51.0% below its 52-week high of $7.13 and 72.2% above its 52-week low of $2.03. Over the past year, it lost 31.3%. Galectin Therapeutics Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 17, 2025, GALT closed higher on 116 days (46%). Its best day was June 24, 2026 (+25.64%) and its worst was December 19, 2025 (-28.90%). The stock moved 10% or more in a single session 19 times. It opened at least 5% above the previous day's high 1 time.
Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company's lead product candidate includes galectin-3 inhibitor (GR-MD-02), a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis. The company, through its collaborative joint venture, Galectin Sciences, LLC with SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia.
Find more stocks like GALT with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.